Compare Eli Lilly And Co (LLY) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Workiva Inc — how do they compare? Eli Lilly And Co trades at $1,219.36 (market cap $1.08T), while Workiva Inc trades at $67.88 (market cap $3.76B). The key difference: Eli Lilly And Co is far larger — about 287.2× Workiva Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| LLY | WK | |
|---|---|---|
Market Cap | $1.08T | $3.76B |
Sector | Health | Technology |
52-Week High | $1.24K | $93.31 |
52-Week Low | $639.43 | $44.31 |
Enterprise Value | $1.13T | $3.73B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
WK trades at $67.73, up 0.61% today, near its consensus price target of $69. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $966 million in 2026 with net income turning positive at $47 million, reflecting improved profitability. Positive sentiment is driven by AI product launches and consistent earnings outperformance.
Outlook remains positive given earnings momentum and AI innovation, but high valuation multiples pose risks. Investors face elevated P/E and EV/EBITDA ratios, requiring sustained growth to justify premiums. Competitive pressures and execution on AI initiatives are key to maintaining upward trajectory amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
